Construction and validation of a novel ten miRNA-pair based signature for the prognosis of clear cell renal cell carcinoma

被引:0
作者
Wang, Yulin [1 ,2 ,3 ]
Shen, Ziyan [1 ,2 ,4 ]
Mo, Shaocong [5 ]
Dai, Leijie [6 ]
Song, Biao [7 ]
Gu, Wenchao [8 ]
Ding, Xiaoqiang [1 ,2 ,3 ,4 ]
Zhang, Xiaoyan [1 ,2 ,3 ,4 ,9 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Nephrol, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Shanghai Med Ctr Kidney Dis, Shanghai 200032, Peoples R China
[3] Shanghai Key Lab Kidney & Blood Purificat, Shanghai 200032, Peoples R China
[4] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
[5] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai 200040, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200032, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Dermatol, Beijing 100005, Peoples R China
[8] Gunma Univ, Dept Diagnost Radiol & Nucl Med, Grad Sch Med, Maebashi 3718511, Japan
[9] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2022年 / 25卷
关键词
miRNA-pair; ccRCC; Prognosis; Signature; Immune; Bioinformatics; CANCER; EXPRESSION; METASTASIS; MODELS; IDENTIFICATION; ENCYCLOPEDIA; MICRORNAS; DISCOVERY; CELLMINER; NOMOGRAM;
D O I
10.1016/j.tranon.2022.101519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Clear cell renal cell carcinoma (ccRCC) is the most predominate pathological subtype of renal cell carcinoma, causing a recurrence or metastasis rate as high as 20% to 40% after operation, for which effective prognostic signature is urgently needed. Methods: The mRNA and miRNA profiles of ccRCC specimens were collected from the Cancer Genome Atlas. MiRNA-pair risk score (miPRS) for each miRNA pair was generated as a signature and validated by univariate and multivariate Cox proportional hazards regression analysis. Functional enrichment was performed, and im-mune cells infiltration, as well as tumor mutation burden (TMB), and immunophenoscore (IPS) were evaluated between high and low miPRS groups. Target gene-prediction and differentially expressed gene-analysis were performed based on databases of miRDB, miRTarBase, and TargetScan. Multivariate Cox proportional hazards regression analysis was adopted to establish the prognostic model and Kaplan-Meier survival analysis was performed. Findings: A novel 10 miRNA-pair based signature was established. Area under the time-dependent receiver operating curve proved the performance of the signature in the training, validation, and testing cohorts. Higher TMB, as well as the higher CTLA4-negative PD1-negative IPS, were discovered in high miPRS patients. A prognostic model was built based on miPRS (1 year-, 5 year-, 10 year-ROC-AUC=0.92, 0.84, 0.82, respectively). Interpretation: The model based on miPRS is a novel and valid tool for predicting the prognosis of ccRCC. Funding: This study was supported by research grants from the China National Natural Scientific Foundation (81903972, 82002018, and 82170752) and Shanghai Sailing Program (19YF1406700 and 20YF1406000).
引用
收藏
页数:16
相关论文
共 93 条
  • [1] Predicting effective microRNA target sites in mammalian mRNAs
    Agarwal, Vikram
    Bell, George W.
    Nam, Jin-Wu
    Bartel, David P.
    [J]. ELIFE, 2015, 4
  • [2] Evaluation of associations between single nucleotide polymorphisms in the FRMD3 and CARS genes and diabetic nephropathy in a Kuwaiti population
    Al-waheeb, S.
    Alwohhaib, M.
    Abdelghani, A.
    Al-Sharrah, S.
    Al-Shafey, E.
    Al-Sahow, A.
    Alyatama, N.
    Dashti, A. A.
    Hussain, N.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2016, 15 (01)
  • [3] Albersen M., CANCERS, V13
  • [4] Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
    Albiges, Laurence
    Powles, Tom
    Staehlerr, Michael
    Bensalan, Karim
    Giles, Rachel H.
    Hora, Milan
    Kuczyk, Markus A.
    Lam, Thomas B.
    Ljungberg, Brje
    Marconi, Lorenzo
    Merseburger, Axel S.
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Fernandez-Pello, Sergio
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2019, 76 (02) : 151 - 156
  • [5] The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
    Angulo, Javier C.
    Manini, Claudia
    Lopez, Jose I.
    Pueyo, Angel
    Colas, Begona
    Ropero, Santiago
    [J]. CANCERS, 2021, 13 (09)
  • [6] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
    Armstrong, Andrew J.
    Halabi, Susan
    Eisen, Tim
    Broderick, Samuel
    Stadler, Walter M.
    Jones, Robert J.
    Garcia, Jorge A.
    Vaishampayan, Ulka N.
    Picus, Joel
    Hawkins, Robert E.
    Hainsworth, John D.
    Kollmannsberger, Christian K.
    Logan, Theodore F.
    Puzanov, Igor
    Pickering, Lisa M.
    Ryan, Christopher W.
    Protheroe, Andrew
    Lusk, Christine M.
    Oberg, Sadie
    George, Daniel J.
    [J]. LANCET ONCOLOGY, 2016, 17 (03) : 378 - 388
  • [7] Arora R.D., 2021, STATPEARLS
  • [8] Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice
    Bao, Rui
    Shui, Xianqi
    Hou, Jiong
    Li, Jinbao
    Deng, Xiaoming
    Zhu, Xiaoyan
    Yang, Tao
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 (03) : 969 - 975
  • [9] The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (vol 483, pg 603, 2012)
    Barretina, Jordi
    Caponigro, Giordano
    Stransky, Nicolas
    Venkatesan, Kavitha
    Margolin, Adam A.
    Kim, Sungjoon
    Wilson, Christopher J.
    Lehar, Joseph
    Kryukov, Gregory V.
    Sonkin, Dmitriy
    Reddy, Anupama
    Liu, Manway
    Murray, Lauren
    Berger, Michael F.
    Monahan, John E.
    Morais, Paula
    Meltzer, Jodi
    Korejwa, Adam
    Jane-Valbuena, Judit
    Mapa, Felipa A.
    Thibault, Joseph
    Bric-Furlong, Eva
    Raman, Pichai
    Shipway, Aaron
    Engels, Ingo H.
    Cheng, Jill
    Yu, Guoying K.
    Yu, Jianjun
    Aspesi, Peter, Jr.
    de Silva, Melanie
    Jagtap, Kalpana
    Jones, Michael D.
    Wang, Li
    Hatton, Charles
    Palescandolo, Emanuele
    Gupta, Supriya
    Mahan, Scott
    Sougnez, Carrie
    Onofrio, Robert C.
    Liefeld, Ted
    MacConaill, Laura
    Winckler, Wendy
    Reich, Michael
    Li, Nanxin
    Mesirov, Jill P.
    Gabriel, Stacey B.
    Getz, Gad
    Ardlie, Kristin
    Chan, Vivien
    Myer, Vic E.
    [J]. NATURE, 2019, 565 (7738) : E5 - E6
  • [10] The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Barretina, Jordi
    Caponigro, Giordano
    Stransky, Nicolas
    Venkatesan, Kavitha
    Margolin, Adam A.
    Kim, Sungjoon
    Wilson, Christopher J.
    Lehar, Joseph
    Kryukov, Gregory V.
    Sonkin, Dmitriy
    Reddy, Anupama
    Liu, Manway
    Murray, Lauren
    Berger, Michael F.
    Monahan, John E.
    Morais, Paula
    Meltzer, Jodi
    Korejwa, Adam
    Jane-Valbuena, Judit
    Mapa, Felipa A.
    Thibault, Joseph
    Bric-Furlong, Eva
    Raman, Pichai
    Shipway, Aaron
    Engels, Ingo H.
    Cheng, Jill
    Yu, Guoying K.
    Yu, Jianjun
    Aspesi, Peter, Jr.
    de Silva, Melanie
    Jagtap, Kalpana
    Jones, Michael D.
    Wang, Li
    Hatton, Charles
    Palescandolo, Emanuele
    Gupta, Supriya
    Mahan, Scott
    Sougnez, Carrie
    Onofrio, Robert C.
    Liefeld, Ted
    MacConaill, Laura
    Winckler, Wendy
    Reich, Michael
    Li, Nanxin
    Mesirov, Jill P.
    Gabriel, Stacey B.
    Getz, Gad
    Ardlie, Kristin
    Chan, Vivien
    Myer, Vic E.
    [J]. NATURE, 2012, 483 (7391) : 603 - 607